The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Lymphoma tumor microenvironment updates
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, provides an overview of our current understanding of the tumor microenvironment. While there are now a variety of strategies used to target the tumor cell, Prof Ansell asserts that the future is going to be a combination of these. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding: Bristol Myers Squibb, Seattle Genetics, ADC Therapeutics, Affimed, Trillium, AI Therapeutics, Regeneron
